Business
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
HENDERSON, Nev., May 13, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts.
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7812afb2b6b493d328df2c3b7e63a147"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l948ExFxHjh4Nq94C6QJfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7812afb2b6b493d328df2c3b7e63a147","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MvcV0Gn9K0a9MGcWyZ7_Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7812afb2b6b493d328df2c3b7e63a147","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zJQjpBpZ8ER_Mhi.2idDAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7812afb2b6b493d328df2c3b7e63a147","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HENDERSON, Nev., May 13, 2026--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts.","length":503,"tagName":"p"},{"type":"text","content":"Mr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology experience to Zura, with extensive experience in immunology, rare disease, and other therapeutic areas. Most recently, he served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played an integral part in the global launch and commercialization strategies of two innovative medicines in orphan diseases. He subsequently led integration planning for Amicus in connection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of the company. Earlier in his career, Mr. Mustufa held roles at GSK plc, The Frankel Group, and The D.E. Shaw Group.","length":652,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Muz to Zura as we approach key clinical and corporate milestones for tibulizumab," said ...